Skip to main content

Table 2 Comparison of biochemical parameters among PC patients, patients with benign pancreatic diseases and healthy volunteers

From: Evaluation of serum ATX and LPA as potential diagnostic biomarkers in patients with pancreatic cancer

Variables

PC patients

(n = 114)

Patients with BPDs

(n = 94)

HVs

(n = 120)

p value (s)

Median (range)

Median (range)

Median (range)

PC vs. BPDs

PC vs. HVs

Total bilirubin, µmol/L

44.8 (19.2–141.5)

9.16 (6.3–72.8)

7.24 (3.68–15.1)

 < 0.001

< 0.001

Albumin, g/L

31.48 (20.1–83.5)

42 (39.7–65.4)

51.3 (27.1–168.3)

< 0.001

< 0.001

Alanine transaminase, U/L

42 (34.1–144)

24.3 (24.3–59.5)

18.8 (13.3–41)

< 0.001

< 0.001

Aspartate aminotransferase, U/L

116.9 (62–328.4)

37.5 (27.9–212.4)

27.2 (18–59.6)

< 0.001

< 0.001

Alkaline phosphatase, U/L

109.7 (39.2–247.6)

80.4 (19.3–169.2)

71.2 (41.5–145.2)

0.008*

0.005*

γ-glutamyl transferase, U/L

102.3 (77.5–201.2)

51.4 (25–110.2)

44.7 (37.2–88.6)

0.005*

0.004*

Glucose, mmol/L

9.3 (8.8–28.7)

8.7 (3.4–42.6)

4.5 (4.1–8.2)

0.086

< 0.001

Creatinine, µmol/L

87.3 (45.3–143.3)

71.2 (19.3–95.5)

64.7 (32.6–213.8)

0.043*

0.027*

Prothrombin time, sec

17.3 (4.5–56.1)

18.4 (8.7–92.6)

12.6 (10.6–58)

0.074

0.018*

Activated partial prothrombin time, sec

44.5 (37.4–103.5)

27.3 (10.9–90.1)

30.5 (22.2–67.5)

< 0.001

< 0.001

D-dimer, µg/mL

0.8 (0.4–2.3)

0.3 (0.08–1.9)

0.2 (0.03–1.2)

< 0.001

< 0.001

  1. BPDs, benign pancreatic diseases; HVs, healthy volunteers
  2. *Depicts results were significant at p < 0.05